Transcription of 敗血症性ショック時に - Hospitalist
1 2018 6 Q-SOFA3 Sepsis 3 BT C, PR 92bpm,reg-reg, BP 64/38 mmHg, RR 28cpm, SpO2 93% ( ), GCS E2V3M4 77 ABPC/ SBT 3g shock vital (NAD) (AVP) CT septic shock ICU SOFA 14 77 AVP Clinical Question NAD AVP EBM 5 stepsStep 1 (PICO) Step 2 Step 3 Step 4 Step 5 Step1-4 Step 1 P:NAD AVP I:NAD C:AVP O: Step 2 PubMed 2017 10 1 : septic shock, discontinuation,norepinephrine, vasopressin.
2 2 sample size AVP AVP AVP V1 AVP ACTH SSCG 2016 NAD CritCare Med. 2001;29(3):487 93. Am J Physiol. 1997;272(3 Pt 2):H1087-93. CritCare Med. 2007;35(1):33 Med. 2017;45(3):486 552. 3 AVP AVP AVP SSCG AVP NAD JAMA. 2016;315(8):801 Med. 2017;45(3):486 552. J Crit Care. 2010;25(2) EnglJ Med. 2008;358(9):877 Med. 2002;30(3):497 500. AVPStep 3 PICOP:NAD AVP I:AVP C:NAD O: 2014 5 2016 7 3 (332 ICU 52 ) Patient Inclusion criteria 18 (sepsis 3 ) NAD AVP Exclusion criteria 2 / NAD AVP 6 ICU 48 Intervention/ Comparison Intervention AVP Comparison NAD Outcome Primary endpoint : MAP 60 mmHg and or or 500ml 500ml/ h or 5% 500ml 500ml/ h Secondary endpoint ICU 28 AVP NAD / student t Pearson 2 Fisher 31 = , 1 =.
3 40% J Crit Care. 2010;25(2) 31 AVP 62 NAD 92 346 62 AVP 92 NAD 192 81 AVP, NAD 40 23 48 17 10 HD 3 1. Inclusion and Exclusion COPD DOA/ DOB DM 1. Baseline and Clinical Characteristics 28 Primary endpoint: 2 Secondary endpoint: ICU 300 Primary endpoint: AVP Secondary endpoint: AVP NAD AVP AVP 2 2. UnivariateAnalyses Primary endpoint: AVP Secondary endpoint: 2 3.
4 Adjusted Logistic Regression Outcome Results Strong pointLimitationDOA/DOB AVP NAD AVP DOA/DOB 2 NAD 2 ICU 300 AVP + NAD 28 Step 4 NAD NAD AVP Step 5 Step 1 -4 Step 1 PICO Step 2 PubMed Step 3 Step 4 NAD AVP / AVP RCT
